Aligos Therapeutics, Inc. (ALGS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Lawrence M. Blatt MBA, Ph.D.
|
CEO, President & Chairman of the Board | 1.04M | -- | 1962 |
|
Ms. Lesley Ann Calhoun CPA
|
Executive VP, CFO & COO | 704.76k | -- | 1966 |
|
Dr. Julian A. Symons DPHIL
|
Executive VP & Chief Scientific Officer | 693.98k | -- | 1962 |
|
Mr. Nikhil Aneja
|
Principal Accounting Officer | -- | -- | 1977 |
|
Ms. Laura Kavanaugh
|
VP & Head of Legal | -- | -- | -- |
|
Ms. Kristina Engeseth M.B.A.
|
Senior VP and Head of People & Culture | -- | -- | -- |
|
Dr. Sushmita M. Chanda DABT, Ph.D.
|
Executive Vice President & Chief Development Officer | -- | -- | 1967 |
|
Dr. David B. Smith Ph.D.
|
Executive VP & Head of Chemical Operations | -- | -- | -- |
|
Dr. Tse-I Lin Ph.D.
|
Senior VP of Early Compound Development & Belgian Site Head | -- | -- | -- |
|
Dr. Kieron Wesson Ph.D.
|
Vice President & Head of Chemistry Manufacturing Controls | -- | -- | -- |
Aligos Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 82
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
Aligos Therapeutics, Inc. Earnings Date
